[1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridin-3-yl]urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: [1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridin-3-yl]urea
• 英文别名: [1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridin-3-yl]urea
• 化学式: C₂₅H₂₆N₆O₄
• 分子量: 474.5
• InChiKey: WVNSIXQAWHSWDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER
  申请人：ratiopharm GmbH

  公开号：EP2854759A1

  公开（公告）日：2015-04-08
• [EN] DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER<br/>[FR] FORMES DE DOSAGE COMPRENANT APIXABAN ET UN AGENT DE FORMATION DE MATRICE
  申请人：RATIOPHARM GMBH

  公开号：WO2013174498A1

  公开（公告）日：2013-11-28

  The invention relates to oral dosage forms for modified release of apixaban. The invention also relates to methods of preparing said dosage forms and to an agglomerated mixture of matrix former and filler for preparing an oral dosage form for use in the treatment of venous thromboembolism.